| Literature DB >> 35538132 |
Debsopan Roy1, Sumit Mukherjee2, Aroni Chatterjee1, Hiya Ghosh3, Agnibha Maiti4, Rivu Basu5, Nilanjan Chakraborty6.
Abstract
During advanced HIV infection, Human Cytomegalovirus (HCMV) has been proven to produce devitalizing end-organ diseases (EOD). The interactive co-existence of HIV and HCMV has been reported by many researchers and has been suggested to be linked with a more aggressive disease state. This study has been designed to bring forward an assessment of the clinical risk factors capable of defining the conditions of HCMV induced retinitis and gastro-enteric diseases among HIV1 seropositive patients. We also intended to analyse the phylogenetic variation if any, among the infecting virus types inducing the two separate clinical conditions. The patients were arranged in three different groups; (Group 1 with 26 individuals and group 2 and group 3 with 25 individuals each) based on their current status of HIV and HCMV infections. Serum ELISA, qualitative and quantitative detection of HCMV DNA, Real time mRNA expression study, sequencing, and phylogenetic analysis were performed. All statistical analyses and graphs were exercised using relevant software. We found that in HIV patients with HCMV induced end-organ diseases the components of the CXCL9, 10, 11-CXCR3 chemokine pathway is highly expressed with significant differences existing among patients with retinitis and gastrointestinal disease. We found that the gL gene sequences from the retinitis (HR) group clustered almost separately from that of the gastroenteritis (HG) group in the phylogenetic tree. It may be suggested that a form of natural selection pressure is working on the clinical HCMV strains creating a slight divergence in their phylogenetic lineage thereby helping them adapt to the particular tissue microenvironment they are colonizing.Entities:
Mesh:
Year: 2022 PMID: 35538132 PMCID: PMC9091246 DOI: 10.1038/s41598-022-11727-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
A comparative analysis of the demographic and hematological parameters of the patients measured at the time of admission, differentiating Group 1 (N = 26) from Group 2 (N = 25) and Group 3 (N = 25).
| Parameters | Groups | Mean ± SD | Significance | 95% CI |
|---|---|---|---|---|
| Age (years) | Group 1 | 39.92 ± 10.2 | Constant | Constant |
| Group 2 | 40.93 ± 8.85 | 1.00 | − 10.75 to 8.75 | |
| Group 3 | 40.2 ± 11.16 | 1.00 | − 9.95 to 9.55 | |
| BMI | Group 1 | 19.57 ± 1.6 | Constant | Constant |
| Group 2 | 20.08 ± 1.52 | 1.00 | − 2.35 to 1.35 | |
| Group 3 | 21.68 ± 2.64 | 0.02 | − 3.94 to − 0.0265 | |
| Hemoglobin (g/dL) | Group 1 | 7.33 ± 0.96 | Constant | Constant |
| Group 2 | 7.71 ± 1.06 | 1.00 | − 1.53 to 0.78 | |
| Group 3 | 8.84 ± 1.65 | 0.007 | − 2.66 to − 0.35 | |
| Total WBC (× 109/L) | Group 1 | 3.61 ± 0.93 | Constant | Constant |
| Group 2 | 3.85 ± 0.49 | 1.00 | − 1.257 to 0.774 | |
| Group 3 | 4.04 ± 1.56 | 0.91 | − 1.45 to 0.592 | |
| CD4+ T cell count (/mm3) | Group 1 | 62.15 ± 20.24 | Constant | Constant |
| Group 2 | 170.9 ± 63.14 | 0.00 | − 148.67 to − 68.83 | |
| Group 3 | 346.2 ± 45.77 | 0.00 | − 323.9 to − 244.13 | |
| Neutrophil (×109/L) | Group 1 | 0.49 ± 0.24 | Constant | Constant |
| Group 2 | 0.72 ± 0.21 | 0.032 | − 0.44 to − 0.015 | |
| Group 3 | 0.94 ± 0.18 | 0.00 | − 0.656 to − 0.231 | |
| Monocytes (×109/L) | Group 1 | 1.68 ± 0.57 | Constant | Constant |
| Group 2 | 1.58 ± 0.41 | 1.00 | − 0.392 to 0.585 | |
| Group 3 | 1.33 ± 0.41 | 0.246 | − 0.14 to 0.837 | |
| Platelets (×109/L) | Group 1 | 76.9 ± 18 | Constant | Constant |
| Group 2 | 88.8 ± 5.69 | 0.132 | − 26.25 to 2.407 | |
| Group 3 | 96.3 ± 10.9 | 0.005 | − 33.71 to − 5.16 | |
| Hematocrit (%) | Group 1 | 18.52 ± 3.57 | Constant | Constant |
| Group 2 | 38.22 ± 6.44 | 0.01 | − 24.32 to − 15.06 | |
| Group 3 | 51.1 ± 4.98 | 0.00 | − 37.2 to − 27.94 | |
| Erythrocyte sedimentation rate (mm/h) | Group 1 | 97 ± 17.32 | Constant | Constant |
| Group 2 | 95.14 ± 8.98 | 1.00 | − 11.74 to 15.46 | |
| Group 3 | 90.53 ± 9.57 | 0.721 | − 7.132 to 20.07 | |
| HIV viral load (×103 copies/mL) | Group 1 | 327.9 ± 155.8 | Constant | Constant |
| Group 2 | 318.44 ± 123.8 | 1.00 | − 114.7 to 133.6 | |
| Group 3 | 78.9 ± 24.45 | 0.00 | 124.7 to 373.1 | |
| HCMV viral load (×103 copies/mL) | Group 1 | 116.84 ± 51.62 | Constant | Constant |
| Group 2 | 35.18 ± 7.16 | 0.00 | 45.56 to 117.7 | |
| Group 3 | – | – | – |
Mean ± SD values were calculated and one way ANOVA was performed using Bonferroni method (Post-hoc analysis) for comparing the mean values of each group with respect to that of Group 1.
A comparative analysis of the different immunological parameters of the patients measured at the time of admission, differentiating Group 1 (N = 26) from Group 2 (N = 25) and Group 3 (N = 25).
| Parameters | Groups | Mean ± SD | Significance | 95% CI |
|---|---|---|---|---|
| TGFβ (pg/mL) | Group 1 | 250.32 + 55.9 | Constant | Constant |
| Group 2 | 187.98 + 16.15 | 0.001 | 21.96 to 102.73 | |
| Group 3 | 121.83 + 15.79 | 0.001 | 88.11 to 168.87 | |
| IL10 (pg/mL) | Group 1 | 27.12 + 4.95 | Constant | Constant |
| Group 2 | 29.03 + 5.98 | 1.00 | − 7.59 to 3.77 | |
| Group 3 | 35.86 + 7.3 | 0.001 | − 14.43 to − 3.05 | |
| IL7 (pg/mL) | Group 1 | 180.12 ± 23.54 | Constant | Constant |
| Group 2 | 190.9 ± 10.38 | 0.62 | − 31.73 to 10.17 | |
| Group 3 | 184.5 ± 25.22 | 1.00 | − 25.36 to 16.54 | |
| IFNγ (pg/mL) | Group 1 | 23.57 ± 6.83 | Constant | Constant |
| Group 2 | 17.84 ± 2.25 | 0.04 | 0.204 to 11.26 | |
| Group 3 | 14.5 ± 5.42 | 0.001 | 3.54 to 14.59 | |
| TNFα (pg/mL) | Group 1 | 127.25 + 26.13 | Constant | Constant |
| Group 2 | 96.21 ± 7.92 | 0.001 | 11.602 to 50.48 | |
| Group 3 | 40.79 ± 11.92 | 0.002 | 67.02 to 105.9 | |
| IL6 (pg/mL) | Group 1 | 32.6 ± 8.04 | Constant | Constant |
| Group 2 | 37.6 ± 7.17 | 0.272 | − 12.81 to 2.32 | |
| Group 3 | 30.05 ± 7.84 | 1.000 | − 5.2 to 9.92 | |
| IL1β (pg/mL) | Group 1 | 123.98 + 38.72 | Constant | Constant |
| Group 2 | 91.64 + 7.3 | 0.016 | 4.86 to 59.87 | |
| Group 3 | 45.72 + 9.07 | 0.001 | 50.75 to 105.7 | |
| CRP (mg/L) | Group 1 | 19.04 + 2.69 | Constant | Constant |
| Group 2 | 18.09 + 2.4 | 1.00 | − 1.64 to 3.55 | |
| Group 3 | 7.96 + 2.25 | 0.001 | 8.48 to 13.68 | |
| MCP1 (pg/mL) | Group 1 | 611.33 + 56.1 | Constant | Constant |
| Group 2 | 603.28 + 41.23 | 1.00 | − 45.46 to 61.56 | |
| Group 3 | 472.55 + 64.23 | 0.001 | 85.25 to 192.28 | |
| MIP1α (pg/mL) | Group 1 | 39.05 + 9.49 | Constant | Constant |
| Group 2 | 37.64 ± 12.73 | 1.00 | − 8.25 to 11.07 | |
| Group 3 | 37.11 ± 7.37 | 1.00 | − 7.72 to 11.6 | |
| CXCL10 (pg/mL) | Group 1 | 884.3 ± 58.8 | Constant | Constant |
| Group 2 | 569.9 ± 55.7 | 0.001 | 263.7 to 364.8 | |
| Group 3 | 403.15 ± 26.6 | 0.001 | 430.6 to 531.6 |
Mean ± SD values were calculated and one way ANOVA was performed using Bonferroni method (Post-hoc analysis) for comparing the mean values of each group with respect to that of Group 1.
Binary logistic regression analysis of the selected significant heamatological and immunological factors to ascertain their role while significantly comparing between HCMV induced Retinitis (HR; N = 15) and HCMV induced Gastroenteric disease (HG; N = 11) cases among HIV infected Group 1 patients.
| Parameters | Mean ± SD | Significance | Beta coefficient | 95% CI | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| HR | 52.3 ± 16.4 | 0.052 | 1.069 | 1.00 | 1.143 |
| HG | 72 ± 19.48 | ||||
| HR | 0.51 ± 0.22 | 0.746 | 0.535 | 0.012 | 23.406 |
| HG | 0.48 ± 0.27 | ||||
| HR | 17.95 ± 4.17 | 0.465 | 1.102 | 0.85 | 1.43 |
| HG | 19.1 ± 2.95 | ||||
| HR | 92.98 ± 44.5 | 0.035 | 1.025 | 0.998 | 1.053 |
| HG | 140.7 ± 48.8 | ||||
| HR | 288.65 ± 35.31 | 0.016 | 0.957 | 0.924 | 0.992 |
| HG | 212 ± 45.66 | ||||
| HR | 102.96 ± 7.63 | 0.033 | 1.652 | 0.886 | 1.642 |
| HG | 151.55 ± 8.47 | ||||
| HR | 95.43 ± 11.46 | 0.022 | 1.207 | 0.987 | 1.475 |
| HG | 152.53 ± 34.9 | ||||
| HR | 922.53 ± 47.9 | 0.02 | 0.963 | 0.933 | 0.994 |
| HG | 844.02 ± 41.96 | ||||
| HR | 25.28 ± 7.41 | 0.266 | 0.921 | 0.798 | 1.064 |
| HG | 21.96 ± 6.09 | ||||
Figure 1Receiver operating curves (ROC) for identifying the significant biomarkers defining HCMV induced retinitis associated with best predictive accuracy (area under the curve > 0.8).
Figure 2Differential mRNA expression of some selected chemokines and cytokines from patients belonging to the two different groups (N = 15). Their relative mRNA expression ratio with respect to group 3 control group (Baseline expression) in terms of fold change (2−ΔΔCt) were estimated by quantitative real time PCR. GAPDH mRNA served as internal control (+ 1 value in Y axis was considered to be the baseline of control, with values greater than 1 suggesting positive fold change and values below 1 upto 0 as negative fold change.
Figure 3Differential mRNA expression of CXCR3-CXCL axis components from patients belonging to group 1 with either HCMV induced end organ retinitis (HR) or gastro-enteritis (HG) (N = 11). Their relative mRNA expression ratio with respect to group 3 control group (Baseline expression) in terms of fold change (2−ΔΔCt) were estimated by quantitative real time PCR. GAPDH mRNA served as internal control (+ 1 was considered to be the baseline of control, with values greater than 1 suggesting positive fold change and values below 1 upto 0 as negative fold change).
Figure 4Phylogenetic analysis of the partially sequenced HCMV gL genes from 22 clinical samples belonging to group 1 (11 HR and 11 HG samples) along with 12 standard reference gL gene sequences selected from NCBI database.
Figure 5(A) Structural classification of the conserved consensus gL mRNA local structures belonging to the clinical group with HCMV induced end organ retinitis (HR). (B) Structural classification of the conserved consensus gL mRNA local structure belonging to the clinical group with HCMV induced end organ gastroenteritis (HG).